Feature | January 14, 2014

Boston Scientific Invests in Bioresorbable Stent Startup Amaranth Medical

cath lab stents bioresorbable amaranth fortitude scaffold

January 14, 2014 — Amaranth Medical announced the closing of an equity investment by Boston Scientific Corp. The additional investment capital will be used to advance the clinical development of the Amaranth Fortitude drug-eluting bioresorbable scaffold in a planned international clinical study and subsequent application for CE marking. In addition, the funding will support continued development of the next-generation Fortitude bioresorbable scaffold, which will have thinner struts than any currently available polymeric bioresorbable scaffold.
 
"The properties of the proprietary polymer and the unique manufacturing processes that we developed have allowed us to produce a scaffold with mechanical strength and durability which we believe exceeds that of all currently available bioresorbable scaffolds,” said Kamal Ramzipoor, CEO, Amaranth.
 
The non-drug-eluting Fortitude scaffold was previously evaluated in a study of 13 patients with symptomatic coronary artery disease (CAD), results of which were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting Oct. 27, 2013. The data suggested that the Fortitude scaffold maintained its mechanical integrity, with late lumen loss comparable to that observed with bare metal stents
 
The scaffold is designed to afford the strength of metal stents to assist the artery during the remodeling process following an interventional procedure, without leaving behind a permanent implant with inherent clinical limitations.
 
In 2014, Amaranth will begin enrolling a second cohort of patients to evaluate a drug-eluting Fortitude scaffold.
 
For more information: www.amaranthmedical.com

Related Content

News | Stents

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
News | Stents

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
News | Stents

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
News | Stents

July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions ...

Home July 27, 2023
Home
News | Stents

June 13, 2023 — W. L. Gore & Associates (Gore) announced the initiation of the Gore VBX FORWARD Clinical Study ...

Home June 13, 2023
Home
News | Stents

March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents ...

Home March 05, 2023
Home
News | Stents

January 23, 2023 — A study of more than 100,000 patients has revealed that, for patients with blockages in multiple ...

Home January 23, 2023
Home
News | Stents

July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and ...

Home July 05, 2022
Home
News | Stents

June 2, 2022 — According to the U.S. Food and Drug Administration (FDA), Atrium Medical Corporation is recalling the ...

Home June 02, 2022
Home
News | Stents

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

Home May 13, 2022
Home
Subscribe Now